The North America diverticular treatment market was valued at USD 986.6 million in 2022 and is projected to surpass USD 1.9 billion by 2031, expanding at a CAGR of 7.6% from 2023 to 2031. Market growth is driven by the rising prevalence of diverticular disease, an increasing aging population, growing awareness regarding gastrointestinal health, and advancements in minimally invasive treatment options across the region.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85622

Market Overview

Diverticula are small, bulging pouches that can develop in the lining of the digestive tract, most commonly in the large intestine (colon). When these pouches become inflamed or infected, the condition is known as diverticulitis.

Diverticular treatment refers to the management and medical interventions used to address diverticulitis and its associated symptoms.

The prevalence of diverticular disease has been increasing in North America, posing a significant healthcare challenge. The disease is typically associated with age, and its prevalence tends to increase with advancing age.

Analysts’ Viewpoint

Surge in prevalence of diverticular diseases, rise in healthcare expenditure, and increase in awareness about the disease are driving North America diverticular treatment market demand. Surge in the geriatric population in the region is another factor propelling market progress. Sedentary lifestyle, consumption of diet having low fiber, and intake of high processed foods are expected to bolster North America diverticular treatment market value.

Increase in investment in development of advanced treatment options is projected to offer lucrative opportunities to market players. Post the COVID-19 pandemic, diverticular treatment companies are making data-driven decisions before investing in new products. They are investing significantly in the research and development of advanced diverticular treatment options.

Analysis of Key Players

The competitive landscape is a mix of pharmaceutical giants providing supportive care and medical device leaders specializing in GI diagnostics and intervention.

Leading companies influencing the North American diverticular treatment market include:

• Pfizer, Inc.
• Novartis AG
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Johnson & Johnson
• Mallinckrodt Pharmaceuticals
• Abbott Laboratories
• GSK plc

Strategic moves in 2026 highlight a focus on Precision Diagnostics, with companies like Olympus and Boston Scientific expanding AI-integrated endoscopy to better visualize diverticular bleeding and abscess formation.

Recent Developments (2025–2026)

• In January 2022, the American College of Physicians (ACP) released two new clinical guidelines for the treatment and diagnosis of diverticulitis. These guidelines highlight that the majority of patients with uncomplicated diverticulitis can be effectively treated in outpatient settings. Additionally, it is suggested that some patients may not require immediate antibiotic treatment.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=85622

Key Developments & Trends

• The Antibiotic-Sparing Trend: Increasing evidence that mild, uncomplicated diverticulitis can be managed with observation and diet alone, reducing the use of broad-spectrum antibiotics.
• Microbiome Modulation: Use of specific probiotic strains to restore gut barrier function and prevent recurrence.
• Minimally Invasive Surgery (MIS): Shift toward single-port laparoscopy and robotic surgery for complicated cases requiring resection.
• Digital Symptom Tracking: Adoption of patient-centric apps to monitor abdominal pain and fever, allowing for “just-in-time” clinical interventions.
• Imaging Advancements: Widespread use of ultra-low-dose CT scans and ultrasound for faster, safer bedside diagnosis in emergency departments.

Challenges

• High Recurrence Rates: Approximately 20% to 35% of patients experience a second episode, leading to chronic “revolving door” healthcare costs.
• Diagnostic Overlap: Difficulty in distinguishing diverticulitis from Irritable Bowel Syndrome (IBS) or early-stage Colorectal Cancer without invasive testing.
• Surgical Costs: While MIS improves recovery, the high cost of robotic systems remains a barrier for smaller community hospitals.
• Antibiotic Resistance: Over-prescription in the past has led to challenges in treating severe, perforated cases with standard IV regimens.

Opportunities

• Personalized Nutrition: Development of medical-grade fiber supplements and “colon-friendly” meal kits for post-flare-up recovery.
• Bio-Targeted Therapies: Emerging interest in immunomodulators that target the localized inflammation of the colon wall.
• Ambulatory Surgery Centers (ASCs): Migration of elective resections from high-cost hospitals to specialized outpatient surgical centers.
• Younger Demographic Targeting: Preventive care programs specifically designed for the rising population of millennials with diverticular symptoms.

Market Segmentation

➤ By Type

• Complicated Diverticulitis (Abscess, Perforation, Bleeding – Revenue Leader)
• Uncomplicated Diverticulitis (Fastest Growing ~9.2% CAGR)
• Diverticulosis (Asymptomatic/Preventive care)

➤ By Treatment

• Medications (Antibiotics, Pain Relief, Anti-inflammatories – ~38.7% share)
• Surgery (Laparoscopic/Robotic Colectomy – Projected 7.2% CAGR)
• Supportive Care (IV Fluids, Nutrition, Probiotics)

➤ By Diagnosis

• CT Scan (Market Leader ~41.5% share)
• Ultrasound & Endoscopy
• Blood & Stool Tests

Conclusion

The North America diverticular treatment market in 2026 is defined by conservative management and technical precision. Through 2034, the market will move toward preventive gastrointestinal health. As the industry shifts from emergency hospitalizations to proactive, tech-enabled outpatient care, the companies that lead in early diagnostic accuracy and minimally invasive recovery will capture the largest share of this evolving landscape.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=85622&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com